+

WO2001062264A3 - Halotherapy method by inhalation of sodium chloride - Google Patents

Halotherapy method by inhalation of sodium chloride Download PDF

Info

Publication number
WO2001062264A3
WO2001062264A3 PCT/US2001/005591 US0105591W WO0162264A3 WO 2001062264 A3 WO2001062264 A3 WO 2001062264A3 US 0105591 W US0105591 W US 0105591W WO 0162264 A3 WO0162264 A3 WO 0162264A3
Authority
WO
WIPO (PCT)
Prior art keywords
sodium chloride
inhalation
doses
periods
administered via
Prior art date
Application number
PCT/US2001/005591
Other languages
French (fr)
Other versions
WO2001062264A2 (en
Inventor
Piotr Zawadzki
Valentin Antonovich Vinogradov
Original Assignee
Procter & Gamble
Piotr Zawadzki
Valentin Antonovich Vinogradov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2000104735/14A external-priority patent/RU2000104735A/en
Application filed by Procter & Gamble, Piotr Zawadzki, Valentin Antonovich Vinogradov filed Critical Procter & Gamble
Priority to AU2001241636A priority Critical patent/AU2001241636A1/en
Publication of WO2001062264A2 publication Critical patent/WO2001062264A2/en
Publication of WO2001062264A3 publication Critical patent/WO2001062264A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a convenient yet efficacious method of alleviating the severity or reducing the duration of respiratory ailments, especially the common cold or influenza. The method comprises administering to a person, over a period of from 1 to 14 days, by inhalation from a portable dispenser, one or more doses of sodium chloride, wherein the sodium chloride is in the form of an aerosol of 1 to 5 νm particles and each dose consists essentially of from 50 to 5000 νm sodium chloride, administered via from 2 to 200 inspirations. Suitable dispensers include self-milling dry powder dispensers and liquid nebulisers. Doses are preferably administered via a pulsed regimen comprising two or more periods of sodium chloride inhalation separated by periods of normal breathing. The invention further relates to the use of sodium chloride in the manufacture of a medicament for such methods.
PCT/US2001/005591 2000-02-23 2001-02-22 Halotherapy method by inhalation of sodium chloride WO2001062264A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001241636A AU2001241636A1 (en) 2000-02-23 2001-02-22 Halotherapy method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2000104735/14A RU2000104735A (en) 2000-02-23 HALOTHERAPY METHOD
RU2000104735 2000-02-23

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10257126 A-371-Of-International 2001-02-23
US10/267,708 Continuation-In-Part US6919205B2 (en) 2000-02-23 2002-10-09 Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals
US10/603,226 Continuation-In-Part US7130692B2 (en) 2000-02-23 2003-06-25 Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint

Publications (2)

Publication Number Publication Date
WO2001062264A2 WO2001062264A2 (en) 2001-08-30
WO2001062264A3 true WO2001062264A3 (en) 2002-05-02

Family

ID=20231147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005591 WO2001062264A2 (en) 2000-02-23 2001-02-22 Halotherapy method by inhalation of sodium chloride

Country Status (2)

Country Link
AU (1) AU2001241636A1 (en)
WO (1) WO2001062264A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EE00431U1 (en) * 2003-12-09 2004-04-15 Budarin Vladimir Method for obtaining a salt aerosol at a predetermined concentration
RO122397B1 (en) * 2006-11-14 2009-05-29 Constantin Pascu PROCEDURE AND DEVICE FOR THE CONTROLLED USE OF AIR WATER AEROSOLS
WO2010105991A1 (en) * 2009-03-20 2010-09-23 Livia Tiba Method of creating salt aerosol for breathing by nebulizing an aqueous saline solution
DE102016218604A1 (en) 2016-09-27 2018-03-29 Constantin Adams A particulate mixture, preferably for use in the prophylaxis and / or treatment of an airway disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028944A1 (en) * 1994-04-22 1995-11-02 National Heart & Lung Institute Pharmaceutical inhalation compositions containing a solid active ingredient
US5487378A (en) * 1990-12-17 1996-01-30 Minnesota Mining And Manufacturing Company Inhaler
WO1996031221A1 (en) * 1995-04-05 1996-10-10 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5817028A (en) * 1994-02-25 1998-10-06 Central Sydney Area Health Service Method and device for the provocation of air passage narrowing and/or the induction of sputum
WO1998048875A1 (en) * 1997-04-29 1998-11-05 The Procter & Gamble Company Method of delivering halotherapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487378A (en) * 1990-12-17 1996-01-30 Minnesota Mining And Manufacturing Company Inhaler
US5817028A (en) * 1994-02-25 1998-10-06 Central Sydney Area Health Service Method and device for the provocation of air passage narrowing and/or the induction of sputum
WO1995028944A1 (en) * 1994-04-22 1995-11-02 National Heart & Lung Institute Pharmaceutical inhalation compositions containing a solid active ingredient
WO1996031221A1 (en) * 1995-04-05 1996-10-10 Genentech, Inc. Preparation of sodium chloride aerosol formulations
WO1998048875A1 (en) * 1997-04-29 1998-11-05 The Procter & Gamble Company Method of delivering halotherapy

Also Published As

Publication number Publication date
AU2001241636A1 (en) 2001-09-03
WO2001062264A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
JP5599961B2 (en) Pharmaceutical composition
US20210330635A1 (en) Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
WO2001064182A3 (en) Improvements in or relating to the delivery of oral drugs
MY129384A (en) "pharmaceutical formulations for dry powder inhalers in the form of hard-pellets"
WO2003032928A3 (en) Therapeutic composition and use
KR20010020346A (en) Method of delivering halotherapy
WO2017223566A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
CA2519175A1 (en) A method of treating a systemic disease
US20230158259A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
WO2001062264A3 (en) Halotherapy method by inhalation of sodium chloride
Kunkel et al. Respimat®(a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients
SE0303091D0 (en) Combined doses of tiotropium andfluticasone
O Callaghan et al. The history of inhaled drug therapy
JP2006508994A5 (en)
CZ287114B6 (en) Therapeutic preparation in the form of aerosol and use of gas mixture
RU2362559C2 (en) System of opioids delivery
US20170224936A1 (en) Nasal treatment delivery device with carbon dioxide and saline, and methods
JP2006508993A5 (en)
CN116196298A (en) Aerosol pharmaceutical composition containing glycopyrronium salt and preparation method and application thereof
EP3411094A1 (en) Nasal treatment delivery device with carbon dioxide and saline, and methods, including low flow rates
US20210353536A1 (en) Applying Fluoride for Treating or Preventing Viral Infection Including SARS-CoV-2
JP2002161030A (en) Method for inhaling mixed powder having different particle diameter
RU2000104735A (en) HALOTHERAPY METHOD
D’Amato et al. Double-Blind Crossover Study on the Protective Effect of Fenoterol–Administered by Pressurized Aerosol and in Powder Form–in Allergen-Induced Asthma
WO2004022126A3 (en) Method of treating a systemic disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10257126

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载